LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Aktien・Prothena Corp PLC

Prothena Corp PLC

Geschlossen

BrancheGesundheitswesen

10.31 -4.09

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.19

Max

10.75

Schlüsselkennzahlen
By Trading Economics
Einkommen	89M -37M
Verkäufe	-2M 2.4M
Gewinnspanne	-1,513.085
Angestellte	163
EBITDA	16M -36M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+93.85% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	10M 578M
Vorheriger Eröffnungskurs	14.4
Vorheriger Schlusskurs	10.31

Nachrichtenstimmung

By Acuity

42%

58%

156 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

N/A / 7.35 Unterstützung & Widerstand

Prothena Corp PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Dez. 2025, 22:13 UTC

Ergebnisse

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9. Dez. 2025, 21:40 UTC

Ergebnisse

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9. Dez. 2025, 18:51 UTC

Akquisitionen, Fusionen, Übernahmen

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9. Dez. 2025, 16:57 UTC

Wichtige Markttreiber

Clear Secure Rises on Medicare Identity Verification Contract

9. Dez. 2025, 23:46 UTC

Market Talk

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9. Dez. 2025, 23:46 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings Stake in Lenovo Now at 32.34%

9. Dez. 2025, 23:45 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9. Dez. 2025, 23:44 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9. Dez. 2025, 23:43 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9. Dez. 2025, 23:43 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9. Dez. 2025, 23:35 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9. Dez. 2025, 22:42 UTC

Ergebnisse

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9. Dez. 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Dez. 2025, 21:48 UTC

Market Talk

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9. Dez. 2025, 20:28 UTC

Market Talk

Oil Futures Decline for Second Straight Session -- Market Talk

9. Dez. 2025, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9. Dez. 2025, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Teck Reports Voting Results From Special Meeting of Hldrs

9. Dez. 2025, 20:26 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9. Dez. 2025, 20:21 UTC

Market Talk

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9. Dez. 2025, 19:52 UTC

Ergebnisse

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9. Dez. 2025, 19:17 UTC

Ergebnisse

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9. Dez. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Dez. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. Dez. 2025, 17:11 UTC

Ergebnisse

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Peer-Vergleich

Kursveränderung

Prothena Corp PLC Prognose

Kursziel

By TipRanks

93.85% Vorteil

12-Monats-Prognose

Durchschnitt 20.8 USD 93.85%

Hoch 36 USD

Tief 8 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Prothena Corp PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Prothena Corp PLC – Dist abgegeben haben.

Technischer Score

By Trading Central

N/A / 7.35Unterstützung & Widerstand

All events are bearish.

Stimmung

By Acuity

156 / 374 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.